NIH, Lacks Family Reach Understanding on Genomic Data of HeLa cells - - BioPharm International


NIH, Lacks Family Reach Understanding on Genomic Data of HeLa cells

The National Institutes of Health (NIH) has reached an understanding with the family of the late Henrietta Lacks to allow biomedical researchers controlled access to the whole genome data of cells derived from her tumor, commonly known as HeLa cells. These cells have already been used extensively in scientific research following Lacks death in 1951. The development of modern vaccines, cancer treatments, in vitro fertilization techniques, and other advances. HeLa cells are the most widely used human cell lines in existence today, according to NIH. A recent Nature article, NIH Director Francis S. Collings and NIH Deputy Director for Science, Outreach, and Policy Kathy L. Hudson, describe their collaboration with the family to develop the new policies. They also examine some of the larger questions about protection of research participants in the expanding field of genomics research.

The new controlled access policy for full genome sequence data from HeLa cells will give the Lacks family the ability to have a role in work being done with the HeLa genome sequences and track any resulting discoveries. Under the policy, biomedical researchers who agree to abide by terms set forth in the HeLa Genome Data Use Agreement will be able to apply to NIH for access to the full genome sequence data from HeLa cells. Along with representatives from the medical, scientific, and bioethics communities, two representatives of the Lacks family will serve on NIH’s newly formed, six-member working group that will review proposals for access to the HeLa full genome sequence data. In addition, NIH-funded researchers who generate full genome sequence data from HeLa cells will be expected to deposit their data into a single database for future sharing through this process.

Henrietta Lacks, was treated for cervical cancer at Baltimore’s Johns Hopkins Hospital in 1951. Cells were extracted from the biopsy of her tumor sample for use in research without her knowledge or consent. At the time, there were no federal regulations or restrictions on the use of patients’ cells in research. Although Lacks died shortly afterwards, scientists were able to keep her cancer cells alive and replicating under laboratory conditions. Her cells were the first human cells cuhuricl continuously for use in research, according to NIH.

Source: National Institutes of Health

blog comments powered by Disqus



Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines

Click here